|
CN112251452A
|
|
TIL/TCR-T cell therapy platform
|
|
CN112111460A
|
|
Pharmaceutical compositions of modified cell populations
|
|
CN111826353A
|
|
Methods of modulating T cell function and response
|
|
CN111575297A
|
|
Inducible Fms-related tyrosine kinase 3 ligand modified cells and uses thereof
|
|
CN111548999A
|
|
Modified cells that modulate lymphocyte CD44 pathway and uses thereof
|
|
CN111607596A
|
|
Modified PD-1 and its use in cell therapy
|
|
CN110819596A
|
|
Modified cells with enhanced migratory capacity
|
|
CN110484523A
|
|
A kind of Zinc finger nuclease and its application
|
|
CN110564693A
|
|
An isolated cell or cell line
|
|
CN110540997A
|
|
targeting BCMA chimeric antigen receptor, nucleic acid sequence, vector and application
|
|
CN110257338A
|
|
Chimeric cell factor acceptor
|
|
CN110248677A
|
|
Humanized anti-cd 19 antibodies and its purposes with Chimeric antigen receptor
|
|
WO2017059796A1
|
|
Activation and expansion of t cells
|
|
WO2016138846A1
|
|
Reducing immune tolerance induced by pd‐l1
|
|
WO2017015783A1
|
|
Humanized anti-cd19 antibody and use thereof
|
|
CN106795522A
|
|
The method of directed cloning
|
|
WO2015032340A1
|
|
Modified cells for production of blood cells
|
